Value
5.4/10data confidence 67%| Component | Sub-score |
|---|---|
| P/S | 4.6 |
| Fwd P/E | 4.0 |
| PEG | 10.0 |
| Analyst target | 4.0 |
- ▸Forward P/E: 29.9x
- ▸PEG: 0.14
PTCT · Why this verdict
Why PTC Therapeutics (PTCT) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.7/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The stock is exhibiting strong upward momentum with RSI at 71 (overbought), confirmed volume accumulation from rising OBV, a 2.8x average volume surge on up moves, and a MACD in bullish territory, with the stock trading above its 200-day moving average. Momentum breakdown | Price sustains above its 200-day moving average for at least 6 months without a confirmed reversal below. | →Stable |
| CounterAn RSI of 71 signals overbought conditions, and with the stock already above its analyst price target, the near-term risk of a mean-reversion pullback is elevated. | ||
Free cash flow is -51% of revenue and the company carries no competitive moat, resulting in a business quality score of 3.4/10 that falls below the minimum investable threshold of 4.0, indicating the business is not yet self-sustaining. Quality breakdown | Free cash flow improves to above -20% of revenue within 12 months as the company scales revenue faster than costs. | →Stable |
| CounterBiotechnology companies routinely burn cash during clinical development phases, and the current burn rate may be appropriate given the company's pipeline stage. | ||
The company beat analyst estimates in 3 of the last 4 quarters, including a 93% beat in the most recent quarter where actual EPS came in at -$0.03 versus an estimate of -$0.44, suggesting the losses are narrowing faster than expected. Earnings | Quarterly EPS loss narrows to less than -$0.10 within the next 2 quarters. | →Stable |
| CounterThe one miss in the prior year involved a -1,097% negative surprise, a massive earnings shortfall that highlights the volatility inherent in biotech reporting and the risk of sudden reversals. | ||
Short interest stands at 17% of float with high implied volatility of 90%, and the stock is trading above its options max pain level of $55 by more than 40%, creating meaningful squeeze and violent pullback risk simultaneously. Risk breakdown | Short interest falls below 10% within 12 months as the investment thesis is confirmed and shorts cover. | →Stable |
| CounterHigh short interest in a cash-burning biotech with below-floor business quality may reflect informed short sellers with visibility into execution risk, not just speculative positioning. | ||
The stock is exhibiting strong upward momentum with RSI at 71 (overbought), confirmed volume accumulation from rising OBV, a 2.8x average volume surge on up moves, and a MACD in bullish territory, with the stock trading above its 200-day moving average.
→StableMomentum breakdown
- Expectation
- Price sustains above its 200-day moving average for at least 6 months without a confirmed reversal below.
CounterAn RSI of 71 signals overbought conditions, and with the stock already above its analyst price target, the near-term risk of a mean-reversion pullback is elevated.
Free cash flow is -51% of revenue and the company carries no competitive moat, resulting in a business quality score of 3.4/10 that falls below the minimum investable threshold of 4.0, indicating the business is not yet self-sustaining.
→StableQuality breakdown
- Expectation
- Free cash flow improves to above -20% of revenue within 12 months as the company scales revenue faster than costs.
CounterBiotechnology companies routinely burn cash during clinical development phases, and the current burn rate may be appropriate given the company's pipeline stage.
The company beat analyst estimates in 3 of the last 4 quarters, including a 93% beat in the most recent quarter where actual EPS came in at -$0.03 versus an estimate of -$0.44, suggesting the losses are narrowing faster than expected.
→StableEarnings
- Expectation
- Quarterly EPS loss narrows to less than -$0.10 within the next 2 quarters.
CounterThe one miss in the prior year involved a -1,097% negative surprise, a massive earnings shortfall that highlights the volatility inherent in biotech reporting and the risk of sudden reversals.
Short interest stands at 17% of float with high implied volatility of 90%, and the stock is trading above its options max pain level of $55 by more than 40%, creating meaningful squeeze and violent pullback risk simultaneously.
→StableRisk breakdown
- Expectation
- Short interest falls below 10% within 12 months as the investment thesis is confirmed and shorts cover.
CounterHigh short interest in a cash-burning biotech with below-floor business quality may reflect informed short sellers with visibility into execution risk, not just speculative positioning.
TrendMatrix Research · core thesis
Engine thesis — one sentence
PTC Therapeutics shows exceptional momentum with an RSI of 71, rising OBV, and a 2.8x average volume surge, but is constrained by cash-burning operations with free cash flow at -51% of revenue, low business quality, and an asymmetry ratio of only 0.52 that fails the minimum entry threshold.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
3.4/10data confidence 100%| Component | Sub-score |
|---|---|
| ROA | 0.0 |
| Gross margin | 3.7 |
| Op margin | 6.6 |
| Net margin | 0.0 |
| Current ratio | 8.3 |
| FCF quality | 0.0 |
| Moat | 4.5 |
| Piotroski F | 4.4 |
- ▸Cash-burning: FCF -51% of revenue
- ▸No competitive moat
Growth
10.0/10data confidence 33%| Component | Sub-score |
|---|---|
| EPS growth | 10.0 |
Momentum
8.8/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.0 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 10.0 |
| vol acceleration | 9.0 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
- ▸Volume surge (2.5x avg) on up move
Sentiment
6.0/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 6.8 |
| erm sentiment | 6.4 |
Insider
3.4/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 5.1 |
- ▸Notable insider selling — $9,841,027 (0.142% of mkt cap)
Peer rank
3.7/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.6 |
| quality rank | 2.8 |
| growth rank | 1.3 |
Technical
4.5/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 2.3 |
| support resistance | 2.1 |
| 52w position | 9.0 |
Risk (lower is worse)
4.5/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 0.4 |
| days to cover | 0.7 |
| volatility | 2.7 |
| put call | 10.0 |
| implied vol | 3.1 |
| beta | 9.8 |
- ▸High short interest: 19%
- ▸High IV: 61%
- ▸Concentration risks: 2 MED (10-K Item 1A)
Catalyst
4.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 6.5 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (6)
- MOMENTUM:8.8>=5.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:34d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-0.1=NEGATIVE
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
-0.13
Upside
-1.9%
Downside
15.0%
Sizing output
AVOID
SetupBreakout — Golden cross, above all MAs, RSI 70, MACD bullish
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Growth at 10.0 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:-0.1=NEGATIVE.
The strongest dimensions are Growth at 10.0, Momentum at 8.8, and Sentiment at 6.0; the weakest are Insider at 3.4, Quality at 3.4, and Peer rank at 3.7. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of -0.13 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Price Momentum Surge
Trip ifPrice falls below the 200-day moving average and RSI drops below 40 within 30 days of each other.
- P2Cash Burn Quality Deficit
Trip ifFree cash flow burn exceeds 70% of quarterly revenue for 2 consecutive quarters.
- P3Earnings Improvement Trajectory
Trip ifEPS surprise falls below -50% in at least 2 of the next 4 quarters.
- P4High Short Interest Risk
Trip ifShort interest rises above 20% of float for more than 60 consecutive days.